Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Converge Technology signs GenAI partnership with Forum Systems

Jonathon Brown Jonathon Brown, The Market Online
0 Comments| 13 days ago

{{labelSign}}  Favorites
{{errorMessage}}

  • Converge Technology Solutions (TSX:CTS) signed a Generative AI-focused partnership with Forum Systems to leverage QuantumSim
  • QuantumSim is a secure multi-large language model gateway and Forum Systems is an established name with LLM and application programming interface technologies
  • Converge and Forum’s partnership combines advanced Generative AI capabilities with IT expertise to augment Converge’s advisory role
  • Converge Technology Solutions Corp. opened trading at C$5.35 per share

Converge Technology Solutions (TSX:CTS) signed a Generative AI-focused partnership with Forum Systems to leverage QuantumSim.

The QuantumSim platform is a secure multi-large language model (LLM) gateway and Forum Systems is an established name with LLM and application programming interface (API) technologies.

Converge and Forum’s partnership combines advanced Generative AI (GenAI) capabilities with IT expertise to augment Converge’s advisory role. It will allow clients deep insight into their organizational efficiency as well as enable them to deploy responsible GenAI at scale. Complex business challenges will be addressed through the three modules of QuantumSim.

Those three modules, QS SecureGPT, QS Contracts and QS Benefits can allow clients to quickly analyze contracts with LLMs and standardize benefits language in healthcare and accelerate document discovery and analysis.

“Converge is thrilled to be partnering with Forum Systems on this groundbreaking AI solution for our clients,” Converge’s chief executive officer, Greg Berard, said in a news release. “Artificial Intelligence is at the forefront of today’s technology landscape and it’s imperative to Converge to remain on the cusp of offering the latest innovations in AI and analytics. We’re excited to bring this new offering to market and see it implemented with our valued healthcare clients.”

“Contract management and healthcare benefits are a perfect opportunity to showcase the power of LLMs,” Forum Systems’ chief executive, Mamoon Yunus added. “Combining the deep domain knowledge of Converge with our LLM expertise will prove beneficial to both organizations.”

“GenAI has the potential to transform businesses across industries,” Gartner research analyst Arun Chandrasekaran said in a recent report. “Most business and technology leaders believe that the benefits of GenAI far outweigh its risks, despite the significant risks it poses and potential regulations likely to emerge in the near future.”

Converge Technology Solutions Corp. is a services-led, software-enabled, IT and cloud solutions provider focused on delivering industry-leading solutions.

Click to enlarge
Converge Technology Solutions Corp. stock – April 2023 to April 2024.

Converge Technology Solutions Corp. (TSX:CTS) opened trading at C$5.35 per share and is 40.36 per cent higher in a year.

Join the discussion: Find out what everybody’s saying about this stock on the Converge Technology Solutions Bullboard, and check out the rest of Stockhouse’s stock forums and message boards.

The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.




{{labelSign}}  Favorites
{{errorMessage}}